Health
Congress: Pharma's Price Gouging is Purposeful
Drug Prices
Congress: Pharma’s Price Gouging is Purposeful

New Research Points to How to Reduce the $100 Billion Americans Spend Annually on Unnecessary Health Care
Provider Payment Incentives
New Research Points to How to Reduce the $100 Billion Americans Spend Annually on Unnecessary Health Care
Q&A

Video: Health Care is Not a Functioning Market
Commercial Sector Prices
Video: Health Care is Not a Functioning Market
Video Series: Health Care Prices
Medicare-Medicaid Integration
Fixing the FIDE-SNP — Redefining ‘Fully Integrated’

Maximizing Opportunity, Minimizing Injustice for Our Nation’s Veterans
Drug Prices
Maximizing Opportunity, Minimizing Injustice for Our Nation’s Veterans
Medicare-Medicaid Integration
Improving Behavioral Health Supports for Dual-Eligible Individuals

Drug Pricing Reform Failure is Unacceptable
Drug Prices
Drug Pricing Reform Failure is Unacceptable
Op-Ed

Part 3: After a Groundswell of Success in 2021, Stage is Set for Broader Rx Reform in 2022
Drug Prices
Part 3: After a Groundswell of Success in 2021, Stage is Set for Broader Rx Reform in 2022
Drug Affordability

Part 2: In Quest to Lower Rx Prices, States Deploy New Tools
Drug Prices
Part 2: In Quest to Lower Rx Prices, States Deploy New Tools
Drug Affordability

Part 1: As Congress Debates Lowering Drug Prices, States Waste No Time
Drug Prices
Part 1: As Congress Debates Lowering Drug Prices, States Waste No Time
Drug Affordability

Protecting Patients From the Cost of Surprise Billing is Not Finished
Commercial Sector Prices
Protecting Patients From the Cost of Surprise Billing is Not Finished

Any Public Option Design Must Lower Health Care Costs
Commercial Sector Prices
Any Public Option Design Must Lower Health Care Costs

5 Things to Watch for in the Medicare Trustees’ Report
Medicare Sustainability
5 Things to Watch for in the Medicare Trustees’ Report

Biden Takes Aim at Drug Prices with Executive Order. Does it Go Far Enough?
Drug Prices
Biden Takes Aim at Drug Prices with Executive Order. Does it Go Far Enough?

New Poll: Majority of Voters Want Congress To Take Action To Lower Health Care Prices
Commercial Sector Prices
New Poll: Majority of Voters Want Congress To Take Action To Lower Health Care Prices
Video Series: Health Care Prices

MACPAC Recommends Policies To Reduce Spending on High Cost Specialty Drugs in the Medicaid Program
Drug Prices
MACPAC Recommends Policies To Reduce Spending on High Cost Specialty Drugs in the Medicaid Program

'We Have a Problem': New Alzheimer’s Treatment Reflects Dysfunctional U.S. Drug Market
Drug Prices
‘We Have a Problem’: New Alzheimer’s Treatment Reflects Dysfunctional U.S. Drug Market

Part 2: In No Surprises Act, Arbitration Design Is Key to Realizing Expected Savings
Commercial Sector Prices
Part 2: In No Surprises Act, Arbitration Design Is Key to Realizing Expected Savings

Part 1: Fulfilling the Promises of the Surprise Billing Ban
Commercial Sector Prices
Part 1: Fulfilling the Promises of the Surprise Billing Ban

‘It’s Just Simply the Cost Per Dose That Americans Are Being Charged More For’
Drug Prices
‘It’s Just Simply the Cost Per Dose That Americans Are Being Charged More For’
Q&A

Congress Grills Major Drug Manufacturer on Anticompetitive Tactics and Price Gouging
Drug Prices
Congress Grills Major Drug Manufacturer on Anticompetitive Tactics and Price Gouging

About Us
We strive to maximize opportunity and minimize injustice by investing in systemic solutions that will outlast our funding.